You're watching...
Invivo Therapeutics CEO Frank Reynolds on testing new treatment options for the spinal cord.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Snow -- sometimes -- can sustain.
Well -- -- about this and take a look at this this next product could be a real breakthrough in medicine.
And a real help for people recovering in hospitals.
From the spinal cord injury and -- therapeutics is developing technology that could mean a cure for paralysis.
Joining apple district small business big ideas district -- the is the CEO of -- -- therapeutics is a very interesting very interesting.
This is okay so basically you've been testing this on monkeys and lunches are paralyzed -- -- put in your device.
And that we -- -- -- bleeding and scarring that occurs over the first three weeks after an injury.
Because of the mitigated -- and inflammation.
We get reduced scarring and they get functional recovery that turns energy despair just 10% on the spot -- you need a little bit of -- spared the a lot of cultural recovery would have been rehab program is.
Cord injuries the the crucial timing -- this first three weeks correct correct do you want to be known as -- on the spine and act.
Yes we have up to ten days but we'd like to be learned the first few days of it's my -- wanna be there in the First Act.
Because we do really do have a cascading series of events that occur immediately after -- injury where are you know -- -- testing -- on him exactly reflect just seconds at the end of this year but with the first company ever get a hundred summer -- and -- -- up and running after being paralyzed and its interest.
Nobody ever get a -- you have to being paralyzed up and -- Isn't the first time right this -- happen that's where animal testing have sense okay we've done three studies that we will reporting -- he's in the studies and -- retreated monkeys are up and running in three weeks OK and it but it -- it so let me ask you this up and fun day.
FDA.
Had an interest thing so if I wanna fast track at all.
Actually are we just has met with the FDA in April 12 we got great news only five humans and our first study to trying to sue the FDA they are suffering from -- -- on these patients will be haven't injuries say that day you know come into our senators that we have set up -- -- studies will be to treat them.
We're going to be happening on the really happening at Harvard and then boss and and and outside Philadelphia.
But we are very excited about it.
In this out of MIT -- has such as Harvard and MIT base -- -- -- is number one in the history of life science patents is that MIT's my co-founder.
Bob invented the -- content -- the whole field of tissue engineer regeneration some concepts are using scuffles themselves to regenerate tissue.
-- to their patients today that have bladders in them grown in tanks and labs literally on technology based on bombs.
And of course we have the same patent portfolio we're just using it in spinal cord brain for different applications are just -- you financially right -- rec seem publicly traded on my friends are fairly early on back fast and I look panelists funny here's a gallon -- -- -- this company myself yet.
-- Leon we had did have a lot about people confidence and a spokeswoman offensive and we went public little over a year and a half ago were up a 160%.
About -- -- -- absorption rate that's.
Our viewers can participate when do you think that you will have kind of a sense of that get to that'd be able -- president of the FDA.
Actually -- -- because it's an open label study with the FDA within weeks of -- offers patients -- -- our first patients November 1 of this year and by Christmas you know we would have results that we can tell the world so very excited.
Company to watch and gave up therapeutics and then again you're setting yourself suffering from a an injury in and it's this curse help -- first lyrics are no treatment -- are right -- Reynolds Pacific the first friend Reynolds thank you very much.
